The dual submission decisions for the Jackson Hole Finance Conference 2023 have been sent. If you submitted your paper as a dual submission and did not receive your decision email, please contact us.
“Capital Structure and the Yield Curve” by Diogo Duarte, Ozde Oztekin, and Yuri F. Saporito
Recent estimates suggest that the cost of developing a single new drug in the biopharmaceutical sector is $2.6 billion, confirming the very large amounts of money that medical companies invest to develop a new treatment. Biomedical companies also face the risk of very low rates of success, not only due to the inherent scientific risk of developing… Read More »Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges
Photos from the SFS Cavalcade are now available on the conference website.
The winners of the best paper awards at the CSEF-RCFS Conference on Finance, Labor, and Inequality are: “Owner Culture and Pay Inequality within Firms,” by Jan Bena, Guangli Lu, and Iris Wang “Can the Unemployed Borrow? Implications for Public Insurance,” by J. Carter Braxton, Gordon Phillips, and Kyle Herkenhoff “Early exposure to entrepreneurship and the creation of female entrepreneurs,” by Mikkel Baggesgaard Mertz, Maddalena Ronchi, and Viola Salvestrini The program… Read More »Best Paper Awards at CSEF-RCFS Conference on Labor, Finance, and Inequality
The dual submission decisions for the 4th Future of Financial Information Conference have been sent. If you submitted your paper as a dual submission and did not receive your decision email, please contact us.
Why do firms in the same industry often have different leverage levels? In their paper “Optimal Capital Structure with Imperfect Competition,” Egor Matveyev and Alexei Zhdanov show that strategic interaction alone can generate this difference. The authors first exhibit a theoretical model in which two ex ante identical firms are deciding when to enter an industry and also how much debt to issue. The product price depends both on the… Read More »Paper Spotlight: Optimal Capital Structure with Imperfect Competition
“Understanding Bank Payouts During the Crisis of 2007-2009” by Peter Cziraki, Christian Laux, and Gyongyi Loranth
Recent estimates suggest that the cost of developing a single new drug in the biopharmaceutical sector is $2.6 billion, confirming the very large amounts of money that medical companies invest to develop a new treatment. Biomedical companies also face the risk of very low rates of success, not only due to the inherent scientific risk of developing… Read More »Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges
Leveraged buyouts by private equity funds have been a constant, and growing, phenomenon in corporate finance over the last two decades and their importance is likely to increase in the post-COVID world. Empirical literature on this subject has explored various angles, but one unanswered question is whether the high leverage used in private equity (PE) buyout transactions contributes to the disproportionately high default… Read More »Paper Spotlight: Private Equity and the Resolution of Financial Distress
